We assessed the effect of a new alpha-blocking agent, urapidil, on neuropathic voiding dysfunction, by urodynamic studies. The residual urine volume and rate significantly decreased, whereas the average and the maximum flow rate did not increase significantly. The pressure at maximum flow and minimum urethral resistance decreased significantly. These results suggest that improvement of the voiding dysfunction in some cases could be due to the decreased micturition pressure without increasing the flow rate. The urethral resistance calculated from the pressure/flow data seemed to be a valuable index in evaluating the effects of the drug on neuropathic voiding dysfunction.
Introduction
Alpha-adrenoceptors are known to be pre sent predominantly in the bladder base, posterior urethra and prostate. 1 Alpha blocking agents are reported to reduce the urethral resistance and improve the voiding dysfunction caused by neurological dis order 2 or benign prostatic hyperplasia (BPH). 3 Alpha-blocking agents have been re ported, especially in BPH, to effectively improve the average flow rate (Qave) and maximum flow rate (Qmax) and reduce the residual urine volume and residual urine rate. 4 The reduction in urethral resistance is suggested from the decrease of the maximal urethral closure pressure and prostatic urethral pressure in the urethral pressure profile,s which reflect, however, only the urethral pressure at rest. Minimal urethral resistance (R), calculated from pressure/ flow (p/f) parameters by using the R = PQmax/Qmax 2 (PQmax: pressure at max imum flow) formula is often used as an index representing dynamic urethral resist ance during voiding. 6 Kleeman 7 investigated the effect of an alpha-blocker, phenoxybenzamine (POB), by means of p/f study in seven male and five female dogs. He found that ephedrine, norepinephrine and phenylephrine in creased urethral resistance, whereas POB inhibited these effects, but he could not demonstrate the reduction in urethral resist ance by POB.
Gerstenberg et als studied the effect of POB in patients with BPH and reported the significant increase in Qmax and significant decrease in PQmax and minimal urethral resistance.
Krane et al9 reported the effectiveness of POB on the neuropathic bladder, but they did not evaluate the drug urodynamically. Jensen et allD reported an improvement of uninhibited contraction using prazosin (Minipress®, Phizer, Japan), but they did not report the iP1provement in voiding difficulty. Cramer et alll reported the use fulness of the bladder neck opening test (measurement of the bladder neck diameter in voiding cystourethrography) and measurement of the posterior urethral pressure (pressure at the middle portion between the bladder neck and the external urethral sphincter) during voiding as a means to evaluate the effect of alfuzosin (a new alpha-blocker) in patients with a spinal cord injury. The measurement of the pos terior urethral pressure seems to be mean ingful for the calculation of urethral resist ance during voiding, but it is difficult to use it as a routine procedure because the cath eter should be fixed in a precise position under x-ray monitoring.1 2 There have been few other reports on the efficacy of alpha blockers in voiding difficulties of the neuro pathic bladder patients because it is very difficult to determine standard parameters in the disease which includes supra-and infranuclear types of voiding dysfunctions.
The authors investigated the effect of urapidil (Ebrantil®, Kaken, Japan), a new alpha-blocker, on the voiding dysfunction of the neuropathic bladder by performing p/f studies.
Patients and methods
Fourteen male and 15 female patients with neuropathic bladder (aged 61.4 ± 13.7 years) were studied. The underlying dis eases were brain diseases (seven patients, 24.1 %), spinal cord diseases (six patients, 20.7%), peripheral nervous system diseases (15 patients, 51.7%) and brain disease associated with spinal cord disease (one patient, 3.4%) ( Table I ). Cystometry (CMG) before treatment showed a normal bladder in three patients (10.3%), detrusor hyperreflexia in six (20.7%), low com pliance bladder in 13 (44.8%) and detrusor areflexia in seven (24.1%). In an external sphincter electromyography (ES-EMG), detrusor-external sphincter dyssynergia (DSD) was noted in 11 patients (37.9% ). Uroflowmetry (UFM) was performed in the standing or the sitting position, and the average flow rate (Qave) and maximal flow rate (Qmax) were measured. After UFM, a 12-F two-way catheter was inserted trans urethrally for the measurement of the res idual urine volume (RU). The residual urine rate (RUR) was calculated from the measured residual urine in the following formula: RUR (%) = (RU/(voided volume + RU)) x 100. Water CMG and ES-EMG were carried out in the lithotomy position. When the patient felt a maximal sensation or when the instillation reached 600 ml of water, the catheter was replaced with a 4-F pigtail catheter (Cook Co.) (Fig 1) , and the p/f measurements were carried out in the same position as UFM. In each study, the baseline zero pressure was adjusted to the upper border of the symphysis pubis. In the p/f studies, opening pressure (OP), max imum pressure (Pmax) and pressure at maximum flow (PQmax) were measured in accordance with the criteria of ICS. 13 The minimal urethral resistance (R) was calcul ated by the following formula: R = PQmax/Qmax 2 .6
The patients were treated with urapidil in a dose of 30 mg/day for the first 2 weeks. Patients without satisfactory improvements in symptoms were treated at 60 mg/day for a further 2 weeks. For patients with satisfac tory improvements, the dose was not changed during this 2 week period. The effect of the drug was evaluated mainly from the changes in minimal urethral resistance (R) by calculating the p/f study. The urinary symptoms were scored on a 4-grade scale to assess the symptomatic improvement as reference data for the evaluation of the clinical effect (Table II) .
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Lastly, a paired t-test was used for a statistical analysis of the urodynamic data.
Results
Symptomatic improvement (Table III) The total symptom score was 7.3 ± 3.6 before the treatment and 3.2 ± 2.6 after the treatment (p < 0.01). The improvement in symptom score by 3 or more was noted in 16 cases (55.2%). 
Results of p lf studies
The changes in Qave (from 4.0 ± 3.1 ml/s to 4.5 ± 2.8 ml/s, n = 27) and Qmax (from 10.3 ± 5.7 ml/s to 11.5 ± 5.9 ml/s, n = 28) were insignificant. RU (from 128.7 ± 96.7 ml to 85.6 ± 105.6 ml, n = 29) and RUR (from 42.7 ± 22.5% to 30.1 ± 23.9%, n = 28) significantly decreased (p < 0.05, p < 0.01, respectively) (Fig 2) . In plf studies, op (from 74.0 ± 27.9 cmH 2 0 to 67.0 ± 30.2 cmH 2 0, n = 28) and Pm ax (from 87.3 ± 33.6 cmH 2 0 to 81.1 ±37.2 cmH 2 0, n = 28) showed no significant changes, but PQmax (from 78.0 ± 30.9 cmH 2 0 to 65.5 ± 26.8 cmH 2 0, n = 29) and R (from 2.5 ± 3.1 to 1.2 ± 1.8, n = 29)
significantly decreased (p < 0.05, p < 0.01 respectively) (Fig 3) . R was reduced by 30% or more in 19 cases (65.5%), including 11 cases (37.9%) associated with symptomatic improvement by three points or more as symptom scores. In the remaining eight cases (27.6%), R was improved, but not to a significant degree the symptoms. In another five cases (17.2%), symptom scores were improved, but not with an improvement in R. There was no correlation between the change in R and in symptom scores (Table III) . In a stratified analysis, there were no differences in the improvement of R between sexes, under lying diseases, patterns in CMG before treatment and the presence or absence of DSD.
Discussion
Alpha-blocking agents have been known to reduce urethral resistance, and to be effect ive regarding neuropathic voiding dysfunc tion and urethral obstruction due to benign prostatic hypertrophy. There have been, however, no published reports on the reduc tion of urethral resistance (R) based on the plf study on the neuropathic bladder. R itself is calculated being based on the supposition that the urethra is a rigid pipe. Strictly speaking, the R calculated as above does not represent the real urethral resist ance.14 This parameter, however, is consist ent with the clinical status and it seems to be useful to assess the therapeutic effects of drugs where plf data are used in the same Opening pressure (n = 28)
Before After patients with the same conditions of void ing.
The complexity of the plf study seems to be one of the reasons why it is not utilised as a routine procedure to measure urethral resistance: when a hard catheter is used, insertion is painful and urine sometimes escapes out of the collecting system, and when a soft and straight feeding tube is used, it often slips out during voiding. Suprapubic puncture permits a measure ment of the urethral resistance without placing any instrument in the urethra during urination, but this technique is not suitable as a routine measurement. Thus, the trans urethral technique using a catheter is prefer able in routine clinical practice. Iverson15 transurethrally used a modified 8.3-F J nephrostomy catheter for plf measurements and reported no significant differences in Qave and Qmax between the spontaneous UFM and the plf study. The authors do not recommend this catheter because it is rela tively hard and the width affects urinary flow.6 Using a 4-F pigtail catheter, the authors could perform the plf study in all patients who were able to undergo catheter-free uroflowmetry, and the urinary flow was almost the same as that measured by the UFM.
Alpha-blockers have been reported to reduce residual urine,11 but the amount of residual urine may vary according to the patient's way of continuing straining.
Qave and Qmax are useful parameters to assess voiding difficulties, but no significant changes in Qave and Qmax were found in our previous UFM using an alpha-blocker, moxisylyte (Moxil®, Fuji Revio, Japan),16 or in the present study. We thought the reason may be that Qave and Qmax may vary according to the magnitude and intermit tency of straining in neuropathic bladder patients.
In the previous CMG and ES-EMG stud ies, bladder compliance, detrusor hyper reflexia andlor DSD improved in patients receiving alpha-blockers. 1 0. 16 These para meters are important but applicable only in patients who showed abnormal parameters before treatment. Thus these parameters cannot be applied to all patients with neuro pathic bladder. Thus, the changes in R by measurement of the plf study might be applied in all neuropathic patients with voiding difficulty.
In the present study. POmax and R decreased significantly while Oave and
